Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of recombinant human neuregulin in chronic systolic heart failure
ChiCTR2000034206Phase 3Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neucardin in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: LVESVI change from baseline on day 30. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
neucardin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2000034206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034206.